To the Editor We commend Michalski et al1 for reporting the anticipated results of RTOG 0126, and in particular, for reporting the incidences of both all-cause and cause-specific mortality. Surprisingly, many trials do not report this vital information.2 The incidence of prostate cancer mortality was unexpectedly low in their trial, possibly owing to improvement in salvage therapies and changes in the patient population. We are concerned that the proposed effect size (hazard ratio, 0.77) on overall survival (OS) was, in retrospect, mathematically infeasible, and therefore the true power of this study to detect an OS benefit with dose escalation is much lower than 90%.
Zakeri K, Rose BS, Mell LK. Detecting a Survival Benefit to Dose Escalation. JAMA Oncol. 2019;5(1):109–110. doi:10.1001/jamaoncol.2018.5055
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: